Management plans to provide a comprehensive look at the program, centering on the ongoing ATMOSPHERE and ASCENT trials. The discussion will navigate the existing treatment landscape and the specific hurdles in commercializing sura-vec, also known as ABBV-RGX-314. Beyond internal leadership, the session features a panel of retina experts, including Dr. Gaurav Shah of the California Pacific Medical Center and Dr. Arshad Khanani of Sierra Eye Associates.
REGENXBIO Sets Investor Briefing on Wet AMD Gene Therapy Sura-vec
With pivotal data for surabgene lomparvovec expected by the end of 2026, REGENXBIO is gathering retina specialists and investors in New York on October 20. The event aims to clarify the clinical trajectory of the gene therapy candidate as it nears a critical milestone for treating wet age-related macular degeneration.
Additional speakers include Dr. Lejla Vajzovic from Duke University, Dr. Rahul Khurana of the University of California, and Dr. Ramanath Bhandari from the Springfield Clinic Eye Institute. The meeting, scheduled from 1:00 p.m. to 4:00 p.m. ET, will offer both in-person attendance and a virtual webcast for remote stakeholders. This briefing serves as a final public update before the company releases its anticipated topline data in the fourth quarter of 2026.
Comments (0)
No comments yet. Be the first!